338 completed, 22 unknown, 17 recruiting, 16 terminated. 417 Phase 1, 45 Phase 2.
Follow Dyslipidemias: new trials by email Literature Review of Dyslipidemias trials Research Report on Dyslipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) Drug: EDIT-401, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 1 / Phase 2 | Not yet recruiting | Editas Medicine, Inc. | 56 | 2026-11-01 | 2026-10-26 |
| A Phase 1 Study of VELA-101 in Adult Participants VELA-101, Placebo - Healthy Participants, Hyperlipidemia | Phase 1 | Not yet recruiting | Ursa Medicines | 60 | 2026-11-01 | 2026-10-15 |
| A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers COR-2003, Placebo, COR-1004 + COR-2003 - Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL | Phase 1 | Not yet recruiting | Corsera Health | 108 | 2026-10-01 | 2026-10-05 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly Elevated LDL-C Levels HS-10582, Placebo - Dyslipidemia | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 76 | 2026-09-30 | 2026-08-20 |
| Study of ECC4703 With Sulfasalazine and Pitavastatin ECC4703, Sulfasalazine, Pitavastatin - Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia | Phase 1 | Recruiting | Eccogene | 40 | 2026-08-07 | 2026-09-10 |
| Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers Test Drug, Reference Drug - Hypercholerolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 61 | 2026-08-06 | 2026-09-09 |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B Treatment A(AD-236A), Treatment B(AD-236B), Treatment C(AD-236A+AD-236B) - Hyperlipidemia, Diabete Type 2 | Phase 1 | Not yet recruiting | Addpharma Inc. | 44 | 2026-07-29 | 2026-07-28 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants SAL0167 group, SAL0167 placebo group - Hyperlipidemia | Phase 1 | Not yet recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 120 | 2026-07-21 | 2026-07-23 |
| Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants BMS-986533, Famotidine, Placebo - Healthy Volunteers | Phase 1 | Recruiting | Bristol-Myers Squibb | 136 | 2026-07-13 | 2026-07-24 |
| A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers Investigational Product 1, Investigational Product 2, Investigational Product 1 + Investigational Product 2 - Hypertension, Dyslipidemia | Phase 1 | Recruiting | Korea United Pharm. Inc. | 36 | 2026-07-01 | 2026-07-06 |
| A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) STX-1150 - Elevated LDL-C and High Cholesterol | Phase 1 | Recruiting | Monash University | 64 | 2026-06-30 | 2026-09-21 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205 MWX205, Placebo - Dyslipidemias | Phase 1 | Not yet recruiting | Shanghai Minwei Biotechnology Co., Ltd | 37 | 2026-06-22 | 2026-06-10 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 41 | 2026-06-11 | 2026-07-10 |
| The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg - Healthy, Fasting | Phase 1 | Completed | LG Chem | 28 | 2026-06-11 | 2026-09-10 |
| A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults Laroprovstat/ezetimibe FCDP, Laroprovstat STP, Ezetimibe STP - Healthy Participants | Phase 1 | Completed | AstraZeneca | 18 | 2026-06-10 | 2026-09-28 |
| A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants HRS-1301 Tablets, Atorvastatin Calcium Tablets, Midazolam oral solution - Hyperlipidemias | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 16 | 2026-06-08 | 2026-09-30 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C AD-231, AD-231A, AD-231D and AD-231C - Dyslipidemia, Hypertension | Phase 1 | Not yet recruiting | Addpharma Inc. | 60 | 2026-06-01 | 2026-05-15 |
| Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a) BSA204, Placebo - Dyslipidemias | Phase 1 | Active not recruiting | Bisirna Therapeutics (Suzhou) Co., Ltd. | 40 | 2026-04-20 | 2026-08-19 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults AZD4954, Laroprovstat - Healthy Participants | Phase 1 | Completed | AstraZeneca | 31 | 2026-04-10 | 2026-08-04 |
| A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2 - Healthy Participants | Phase 1 | Completed | AstraZeneca | 44 | 2026-03-16 | 2026-06-17 |
Showing 20 of 417. Sign in to see all of them.
Hyperlipidemias (113) · Hypercholesterolemia (105) · Hypertension (63) · Lecithin Cholesterol Acyltransferase Deficiency (50) · Hypertriglyceridemia (38) · Hyperlipoproteinemia Type II (19) · Cardiovascular Diseases (17) · Obesity (13) · Diabetes Mellitus (12) · Diabetes Mellitus, Type 2 (12) · Atherosclerosis (11) · Metabolic Diseases (11) · Fasting (10) · Lipid Metabolism Disorders (8)
Nutritional and Metabolic Diseases (416) · Lipid Metabolism Disorders (409) · Metabolic Diseases (406) · Hyperlipidemias (133) · Vascular Diseases (81) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (79) · Genetic Diseases, Inborn (77) · Lipid Metabolism, Inborn Errors (77) · Metabolism, Inborn Errors (75) · Cardiovascular Diseases (74) · Hypoalphalipoproteinemias (50) · Hypolipoproteinemias (50) · Glucose Metabolism Disorders (33) · Endocrine System Diseases (25)
Rosuvastatin Calcium (29) · Atorvastatin (24) · Ezetimibe (14) · Metformin (10) · alirocumab (10) · CKD-519 (8) · Drug Evaluation (8) · Niacin (8) · Simvastatin (8) · Telmisartan (8) · Amlodipine (6) · bococizumab (6) · Fenofibrate (5) · MK-0524 (5) · TA-8995 (5)
Chong Kun Dang Pharmaceutical (44) · AstraZeneca (24) · Pfizer (19) · Merck Sharp & Dohme LLC (16) · IPCA Laboratories Ltd. (12) · Par Pharmaceutical, Inc. (11) · Sanofi (9) · Eli Lilly and Company (8) · Addpharma Inc. (7) · Dr. Reddy's Laboratories Limited (7) · Novartis Pharmaceuticals (7) · Yuhan Corporation (6) · Boryung Pharmaceutical Co., Ltd (5) · Bristol-Myers Squibb (5) · Jeil Pharmaceutical Co., Ltd. (5)
United States (126) · South Korea (90) · China (39) · Canada (25) · United Kingdom (25) · Australia (21) · India (18) · New Zealand (9) · Belgium (7) · Germany (7) · Netherlands (6) · Brazil (4) · France (4) · Japan (3) · Moldova (3)
Yook-Hwan Noh, M.D., PhD. (4) · David Han, MD (3) · Ashley Brooks (2) · Dr. Hardik Dave, M.B.B.S. (2)
PMID 37994400, PMID 28181260, PMID 40587053, PMID 24782116, PMID 31776293, PMID 38504437, PMID 14605787, PMID 14662594, PMID 15324521, PMID 18068514, PMID 18201934, PMID 19500003, PMID 19833861, PMID 19843338, PMID 20457158, PMID 21120461, PMID 21252253, PMID 21417623, PMID 21593349, PMID 21831304, PMID 21952084, PMID 22008366, PMID 22435370, PMID 22743313, PMID 22775199, PMID 22970753, PMID 23638799, PMID 23706094, PMID 23713767, PMID 24077434, PMID 24094767, PMID 24206527, PMID 25202920, PMID 25256660, PMID 25393536, PMID 25889044, PMID 25942458, PMID 26179237, PMID 26261033, PMID 26510577, PMID 26607938, PMID 26628614, PMID 27184170, PMID 27287699, PMID 27596224, PMID 27959715, PMID 27986651, PMID 28204912, PMID 28271017, PMID 28279967
2015 (5), 2009 (1), 2019 (1), 2025 (1), K23HL091130 (1), M01RR000334 (1), P01HL059407 (1), R01HL108160 (1), R21AG023805 (1), R21NR011281 (1), U01AI068632 (1), U54DK083912 (1), ZIAHD000641-23 (1)